A phase I safety and immunogenicity trial of a combination vaccine (neftat and gp120w61d) formulated with AS02A (GlaxoSmithKline Biologicals) given intramuscularly in HIV-1 uninfected adult participants.
Phase of Trial: Phase I
Latest Information Update: 22 Nov 2010
At a glance
- Drugs HIV vaccine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- 29 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Oct 2005 New trial record.